Myelodysplastic syndromes: from pathogenesis and prognosis to treatment
- 1 April 2004
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 41, 6-12
- https://doi.org/10.1053/j.seminhematol.2004.02.002
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disordersCancer, 2003
- Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disordersBritish Journal of Haematology, 2003
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaNew England Journal of Medicine, 2002
- Myelodysplastic syndrome is not merely “preleukemia”Blood, 2002
- Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspiratesBlood, 2000
- Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangementsLeukemia, 1999
- MyelodysplasiaNew England Journal of Medicine, 1999
- The Myelodysplastic SyndromesThe Oncologist, 1997
- Is apoptosis a massive process in myelodysplastic syndromes?British Journal of Haematology, 1996
- Myelodysplastic syndromesHematology and Cell Therapy, 1996